TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor
NCT04862767
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
9
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumor
Interventions
DRUG:
TASO-001((TGF-β2 targeting anti-sense oligonucleotide)
COMBINATION_PRODUCT:
Aldesleukin
Sponsor
Autotelicbio